Jupiter Neurosciences, Inc. (JUNS) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 5.17 |
| Open | 8.23 |
| Day High | 11.2 |
| Day Low | 5.5 |
| 52-Week High | 138 |
| 52-Week Low | 4.56 |
| Volume | 49.83M |
| Average Volume | 135,476 |
| Market Cap | 3.18M |
| PE | -24.3 |
| EPS | -0.27 |
| Moving Average 50 Days | 11.95 |
| Moving Average 200 Days | 41.6 |
| Change | 1.39 |
Jupiter Neurosciences to Present at BIO Investment and Growth Summit 2026
GlobeNewswire Inc.
Mar 02, 2026 1:00 PM GMT
Advancing FDA-Cleared Phase IIa Parkinson’s Program Targeting Neuroinflammation Dual-Path Strategy Combines Clinical Development with Revenue-Generating Nugevia™ JUPITER, FL, March 02, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: J
Jupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-Lago
GlobeNewswire Inc.
Feb 25, 2026 1:30 PM GMT
Jupiter Neurosciences, Inc. Jupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-Lago JUPITER, FL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "
Jupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution
GlobeNewswire Inc.
Feb 23, 2026 2:30 PM GMT
Repayment Commencement Deferred to April 1, 2026 Core Economic Terms of $6.0 Million Financing Remain Unchanged JUPITER, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company focus